Syneos Health
pairs early-access pathway design for CNS and oncology assets with its Kinetic AI commercial-intelligence engine, whose KAI Conversations conversation-intelligence module is already used by 10 of the top 20 global pharmaceutical companies.
- Country
- United States
us
commercialization
ai
Coverage
| CN | EU | US | |
|---|---|---|---|
| market-access-commercial | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Named-patient programs & compassionate use | market-access-commercial | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.